{"title":"A prospective, multicenter, randomized, double-blind placebo-controlled trial on purified and specific Cytoplasmic pollen extract for hot flashes in breast cancer survivors.","authors":"Valentina Elisabetta Bounous, Isabella Cipullo, Marta D'Alonzo, Silvia Martella, Dorella Franchi, Paola Villa, Nicoletta Biglia, Annamaria Ferrero","doi":"10.1080/09513590.2024.2334796","DOIUrl":"10.1080/09513590.2024.2334796","url":null,"abstract":"<p><strong>Objective: </strong>evaluate the efficacy and tolerability of PureCyTonin against hot flashes (HF) in breast cancer survivors (BCS).</p><p><strong>Methods: </strong>a prospective, multicenter, randomized, double-blind placebo-controlled trial was conducted in Italy.</p><p><strong>Interventions: </strong>administration of PureCyTonin or placebo, for 3 months. Effectiveness was investigated through the compilation of a daily diary for HF and of validated questionnaires (Menopause Rating Scale (MRS), Pittsburgh Sleep Quality Index (PSQI), Visual Analogical Scales (VAS) for HF, sweating, irritability, fatigue, sleep, quality of life), carried out before starting the treatment (T0), after 1 month (T1) and after 3 months (T2). Any side effects and HF diary were recorded at each visit.</p><p><strong>Results: </strong>19 women were randomized to receive PureCyTonin and 20 to placebo. At T2 compared to T0, in the PureCyTonin group, we found a reduction in the number of HF (<i>p</i> = 0.02) measured by daily diary. An improvement in the subjective perception of women regarding HF intensity (<i>p</i> = 0.04), sweat nuisance (<i>p</i> = 0.02), irritability (<i>p</i> = 0.03) and fatigue (<i>p</i> = 0.04) was observed through VAS scale measurement at T2 compared to T0.The total MRS score was significantly better in the PureCyTonin group at T1 (<i>p</i> = 0.03) compared to T0.</p><p><strong>Conclusions: </strong>PureCyTonin significantly reduces HF number after 3 months of therapy in BCS and it is well-tolerated.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2334796"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brenda Caira-Chuquineyra, Daniel Fernandez-Guzmán, Humberto Garayar-Peceros, Vicente A Benites-Zapata, Faustino R Pérez-López, Juan E Blümel, Edward Mezones-Holguín
{"title":"Efficacy and safety of visnadine in the treatment of symptoms of sexual dysfunction in heterosexual women: a systematic review of randomized clinical trials.","authors":"Brenda Caira-Chuquineyra, Daniel Fernandez-Guzmán, Humberto Garayar-Peceros, Vicente A Benites-Zapata, Faustino R Pérez-López, Juan E Blümel, Edward Mezones-Holguín","doi":"10.1080/09513590.2024.2328619","DOIUrl":"10.1080/09513590.2024.2328619","url":null,"abstract":"<p><strong>Objective: </strong>To synthesize the primary evidence on the efficacy and safety of visnadine on symptoms of sexual dysfunction (SD) in heterosexual women.</p><p><strong>Methods: </strong>We conducted a systematic review of randomized clinical trials (RCTs) with a primary search without language restriction in PubMed/Medline, Scopus, Embase, Web of Science, Cochrane Library, and international clinical trial registries. Trials reporting the use of visnadine by any route in women with SD were eligible. We performed screening, data extraction, and risk of bias assessment in a double-blind approach. The primary outcomes were the Female Sexual Function Index (FSFI) and its domains. Secondary outcomes were safety, arousal, lubrication, pleasure, orgasm, negative sensations, duration, and overall satisfaction.</p><p><strong>Results: </strong>Initially, 242 records were retrieved. We selected nine papers for full-text reading and finally included two RCTs: one with a parallel design and one with a crossover design with a total of 96 patients. One study compared visnadine aerosol with a placebo, while the other compared different frequencies of visnadine aerosol use. Visnadine use showed a statistically significant improvement (<i>p</i> < 0.05) in overall FSFI scores, regardless of the frequency of use. A meta-analysis was not possible due to the high clinical and methodological heterogeneity between available studies.</p><p><strong>Conclusion: </strong>RCTs regarding the use of visnadine for the Female SD are scarce and methodologically limited. This preliminary evidence shows visnadine as a potentially effective and safe option to alleviate some of the clinical symptoms of SD in heterosexual women. However, future better-designed randomized studies with larger sample numbers are required.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2328619"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psychological stressors involved in the pathogenesis of premature ovarian insufficiency and potential intervention measures.","authors":"Ying-Pei Xu, Ji-Chun Fu, Zhi-Lin Hong, De-Fei Zeng, Chao-Qin Guo, Ping Li, Jin-Xiang Wu","doi":"10.1080/09513590.2024.2360085","DOIUrl":"10.1080/09513590.2024.2360085","url":null,"abstract":"<p><p>Premature ovarian insufficiency (POI) is a common gynecological endocrine disease, which seriously affects women's physical and mental health and fertility, and its incidence is increasing year by year. With the development of social economy and technology, psychological stressors such as anxiety and depression caused by social, life and environmental factors may be one of the risk factors for POI. We used PubMed to search peer-reviewed original English manuscripts published over the last 10 years to identify established and experimental studies on the relationship between various types of stress and decreased ovarian function. Oxidative stress, follicular atresia, and excessive activation of oocytes, caused by Stress-associated factors may be the main causes of ovarian function damage. This article reviews the relationship between psychological stressors and hypoovarian function and the possible early intervention measures in order to provide new ideas for future clinical treatment and intervention.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2360085"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Changes in polyunsaturated fatty acids are linked to metabolic syndrome in climacteric syndrome patients.","authors":"Hua Ye, Linju Zhou, Qing Liu, Wanghua Xiao","doi":"10.1080/09513590.2024.2433133","DOIUrl":"https://doi.org/10.1080/09513590.2024.2433133","url":null,"abstract":"<p><strong>Objective: </strong>This study explored the association between ω-6 to ω-3 polyunsaturated fatty acids (PUFAs) and metabolic syndrome in women experiencing climacteric syndrome.</p><p><strong>Methods: </strong>The study involved 186 female participants and utilized surveys, anthropometric measurements (waist circumference, height, BMI, waist-to-height ratio), blood pressure assessments, and blood samples for lipid profile, glucose, insulin, HbA1c analysis. Serum PUFAs levels were analyzed using gas chromatography-mass spectrometry.</p><p><strong>Results: </strong>The study found significantly higher measurements of waist circumference, waist-to-height ratio, systolic and diastolic blood pressure in postmenopausal women with metabolic syndrome compared to the control group. In addition, the metabolic syndrome group showed significantly higher levels of fasting blood glucose, triglycerides, low-density lipoprotein cholesterol, HbA1c, insulin, triglyceride to high-density lipoprotein ratio, and total cholesterol to high-density lipoprotein ratio. Furthermore, the study also identified significant differences among premenopausal women, postmenopausal women with metabolic syndrome, and postmenopausal women without metabolic syndrome in terms of omega-3 alpha-linolenic acid, omega-3 docosahexaenoic acid, omega-6 arachidonic acid, and omega-6 to omega-3 ratio.</p><p><strong>Conclusions: </strong>We observed that high ω-6 arachidonic acid and ω-6/ω-3 ratio and low ω-3 ALA and ω-3 DHA were associated with high TG and WHtR. High TG and WHtR levels in postmenopausal women are associated with increased risk of Mets.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2433133"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Low serum hepcidin levels in women with polycystic ovary syndrome: evidence from meta-analysis.","authors":"Jieou Nong, Hua Li, Yunfei Yang, Qiujie Lu, Yifan Sun, Qi Yin, Hongying He","doi":"10.1080/09513590.2024.2375568","DOIUrl":"10.1080/09513590.2024.2375568","url":null,"abstract":"<p><strong>Background: </strong>Iron metabolism plays a significant role in the development of metabolic disorders in women with polycystic ovary syndrome (PCOS). Despite the importance of hepcidin, a key iron regulator, current research on serum hepcidin levels in PCOS patients shows conflicting results.</p><p><strong>Methods: </strong>PubMed, Embase, Web of Science, Cochrane Library and the China National Knowledge Infrastructure (CNKI) database were systematically searched from their inception to 9 September 2023. The search aimed to identify studies in English and Chinese that examined hepcidin levels in women with PCOS compared to healthy control subjects. Standardized mean differences (SMDs) with corresponding 95% confidence intervals (95% CIs) were calculated to evaluate the difference in serum hepcidin levels between women with and without PCOS.</p><p><strong>Results: </strong>The meta-analysis included a total of 10 eligible studies, which encompassed 499 PCOS patients and 391 control subjects. The pooled analysis revealed a significant reduction in serum hepcidin levels among the PCOS patients compared to the healthy controls (SMD = -3.49, 95% CI: -4.68 to -2.30, <i>p</i> < .05). There was no statistically significant difference in serum hepcidin levels between PCOS patients with a body mass index (BMI) < 25 and those with a BMI ≥ 25 (<i>p</i> > .05).</p><p><strong>Conclusion: </strong>The serum hepcidin levels of women with PCOS were significantly lower than those of healthy controls, which suggests that serum hepcidin could be a potential biomarker for PCOS.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2375568"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ilaria Mazzera, Annalisa Graziano, Giuseppe Vizzielli, Lorenza Driul
{"title":"The role of inositols during pregnancies complicated by gestational diabetes mellitus: a narrative review.","authors":"Ilaria Mazzera, Annalisa Graziano, Giuseppe Vizzielli, Lorenza Driul","doi":"10.1080/09513590.2024.2411727","DOIUrl":"https://doi.org/10.1080/09513590.2024.2411727","url":null,"abstract":"<p><p>Pregnancy is a critical period marked by intricate physiological changes and maintaining maternal and fetal well-being is paramount. Inositols, a group of naturally occurring sugar alcohols, have gained attention for their potential benefits during pregnancy. This abstract provides a comprehensive review of the current literature on using inositols, primarily myo-inositol (MI) and D-chiro-inositol (DCI) in pregnancy. Inositols are crucial in cellular signal transduction and insulin sensitivity, making them integral to various physiological processes. Several studies suggest that inositols may contribute to preventing and managing gestational diabetes mellitus (GDM). MI, in particular, has shown promise in improving insulin sensitivity and mitigating insulin resistance, thereby influencing glucose metabolism. As our understanding of inositol's role in pregnancy deepens, it may emerge as a valuable supplement to enhance maternal and fetal health outcomes.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2411727"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hong Wang, Lun Sui, Qian Xu, Minyu Li, Yuhan Xing, Guoju Li
{"title":"Common obesity-related anthropometric indices and the risk of gestational diabetes mellitus in a Chinese population: a prospective cohort study.","authors":"Hong Wang, Lun Sui, Qian Xu, Minyu Li, Yuhan Xing, Guoju Li","doi":"10.1080/09513590.2024.2390848","DOIUrl":"10.1080/09513590.2024.2390848","url":null,"abstract":"<p><strong>Objective: </strong>Anthropometric measurement provides a simple, noninvasive approach to evaluate obesity in pregnant women. We aimed to develop a predictive model utilizing anthropometric index for gestational diabetes mellitus (GDM), the most common obesity-related complications during pregnancy.</p><p><strong>Methods: </strong>A prospective cohort of 4709 women was enrolled in Qingdao, China. Logistic regression model was constructed to determine the association of body mass index (BMI), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT) in the first trimester (<14 weeks' gestation) with GDM. The discrimination ability for GDM was assessed using areas under the receiver operating characteristic (ROC) curve (AUC). Delong tests were performed to compare AUC values between different measures.</p><p><strong>Results: </strong>The GDM incidence was 19.50%. GDM risk increased with VAT during early pregnancy, and the risk increased by 117% (OR = 2.17, 95% CI: 1.23-2.83) to 326% (OR = 4.26, 95% CI: 2.29-7.91) in pregnant women with the second quartile or above after adjusting for confounders (all <i>p</i><.05). Combined index using VAT and BMI demonstrated superior predictive power for GDM compared with BMI alone (<i>p</i><.05), but didn't differ from VAT (<i>p></i>.05). Overall, VAT was positively correlated with GDM occurrence, outperforming BMI, WHR, WHtR and SAT in the predicative model. A first-trimester VAT cutoff of 27.05 mm might be promising for GDM risk stratification.</p><p><strong>Conclusions: </strong>First-trimester routine ultrasound screening may facilitate earlier identification and intervention of GDM. Pregnant women with VAT above the optimal threshold (27.05 mm) might benefit from targeted GDM monitoring.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2390848"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Statement of Retraction: Luteal support with vaginal dydrogesterone increases pregnancy rate in patients with clomifene resistant polycystic ovary syndrome receiving letrozole for ovulation induction.","authors":"","doi":"10.1080/09513590.2024.2381309","DOIUrl":"10.1080/09513590.2024.2381309","url":null,"abstract":"","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2381309"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lower serum LH level was related to poor embryo quality and adverse pregnancy outcomes in fixed GnRH antagonist protocol with estradiol pretreatment.","authors":"Ying Chen, Yizhe Li, Xu Li, Linhong Liu, Zhen Liu, Wenwu Gui, Xiru Liu, Ying Chen","doi":"10.1080/09513590.2024.2409147","DOIUrl":"https://doi.org/10.1080/09513590.2024.2409147","url":null,"abstract":"<p><strong>Objective: </strong>To disclose the relationships between serum LH and reproductive outcomes in Gonadotropin-releasing hormone (GnRH) antagonist protocol pretreated with luteal estradiol.</p><p><strong>Methods: </strong>371 patients, pretreated with estradiol, followed the GnRH antagonist protocol. They were divided into four groups based on the quartiles of serum LH levels on the day of gonadotropin (Gn) initiation(LH<sub>GI</sub>) and trigger (LH<sub>trigger</sub>). Data on various pregnancy outcomes were collected.</p><p><strong>Results: </strong>As serum LH<sub>GI</sub> increased, anti-Müllerian hormone (AMH) level, antral follicle count (AFC), LH<sub>trigger</sub>, estradiol (E<sub>2</sub>) and P on the trigger day, E<sub>2</sub>/oocytes, and oocyte numbers increased and peaked in Q4, while Gn dose decreased. Good-quality embryo and blast formation rates increased and peaked in Q3. LH<sub>GI</sub> <3.93 mIU/ml impaired ongoing pregnancy rate and LBR. After adjusting for AMH and AFC, the impacts were not significant. As LH<sub>trigger</sub> increased, E<sub>2</sub>/oocytes and good-quality embryo rate increased and peaked in T4 and implantation rate increased and peaked in T3. LH<sub>trigger</sub> <1.49 mIU/ml independently influenced clinical pregnancy rate (CPR) after adjusting for AMH and AFC. LH<sub>GI</sub> was positively related to AMH, AFC, LH<sub>trigger</sub>, blast formation rate and negatively related to BMI, age and Gn dose. LH<sub>trigger</sub> was positively related to E2/oocytes and good quality embryo rate.</p><p><strong>Conclusions: </strong>Lower serum LH represents as a potential indicator for embryo quality and reproductive outcomes in GnRH antagonist fixed protocol pretreated with estradiol. Early identification of excessive suppression of LH levels will benefit individuals with normal ovarian reserve more.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2409147"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Expression of Concern: Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.","authors":"","doi":"10.1080/09513590.2024.2307189","DOIUrl":"10.1080/09513590.2024.2307189","url":null,"abstract":"","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"40 1","pages":"2307189"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140093685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}